MedTrace Logo

Vaginal Progesterone for the Prevention of Preterm Birth in Twins

NCT03540225 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-01-28

No results posted yet for this study

Summary

This trial is a randomised, multi-centre, 2 x 2 factorial designed pilot trial with two factors of 200mg vs. 400mg progesterone self-administered daily from 11-14 weeks' gestation vs. 20-24 weeks' gestation, to compare the median gestational age (in days) at delivery between the comparison groups.

Conditions

  • Premature Birth
  • Twin Pregnancy

Interventions

DRUG

Progesterone

Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week

Sponsors & Collaborators

  • Chiu Yee Liona Poon

    lead OTHER

Principal Investigators

  • Liona CY Poon, MD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2022-04-30
Completion
2022-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03540225 on ClinicalTrials.gov